Lenalidomide plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia (AML) with recurrent genetic abnormalities- AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
ConclusionThe high ORR and reasonable duration of response could allow for potentially curative alloHCT in these high-risk AML patients, and this initial data suggests that lenalidomide plus HMA is a promising approach for patients with AML with inv(3).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Genetics | Leukemia | Lymphoma | Myeloma | Revlimid | Study